Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
2018 FY results
UCB will publish its 2018 full year results on Thursday 28 February 2019.
More details closer to the date.
IR events›
| Date | Event details |
|---|---|
| 12 December 2018 | Exane Healthcare Leaders Forum, Paris1/1 meetings |
| 18 December 2018 | Roadshow in BrusselsBroker: KBC |
| 08 January 2019 | JP Morgan 2019 Annual Healthcare Conference, San Francisco1/1 meetings |
| 09 January 2019 | JP Morgan 2019 Annual Healthcare Conference, San FranciscoPresentation & 1/1 meetings |
Latest News
- 02 Dec 2018 UCB announces approval of VIMPAT® in China
- 30 Nov 2018 UCB and Amgen Announce FDA Advisory Committee Meeting to review EVENITY™ (Romosozumab) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture
- 30 Nov 2018 UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership
Outlook 2018
2018 revenue reporting to reach approximately
€ 4.5-4.6 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
€ 1.3-1.4 billion
Core earnings per share are therefore expected in the range of
€ 4.30-4.70
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
